Skip to main content
SP5007,730.99+0.72%DOW53,569.44+0.20%NASDAQ26,541.35+1.57%BTC$79,383.00+0.14%ETH$2,497.900.00%GOLD$4,643.90-0.43%OIL$82.75-0.93%
Smart Investors Daily
Sign InSign Up Free
LY

NASDAQ · LYEL

Lyell Immunopharma, Inc.

Healthcare · Biotechnology

$14.61

Down-$0.19 (-1.28%)

Updated Aug 28, 2026, 1:00 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
708.04M
P/E ratio
-1.87
Dividend yield
0.00%
52-week range
$10.76 – $45.00
Volume
88.38K
Avg. volume
48.46K

Price performance

LYEL price history

1M range · 21 trading sessions · Daily adjusted prices

LYEL closed at $14.61 after 21 trading sessions, up 6.49% for the selected period.

Last close
$14.61
Period change
+6.49%
Period low
$12.87
Period high
$15.79
Daily close
View OHLC price history
LYEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 27, 2026$14.67$15.02$14.33$14.6188.38K
Aug 26, 2026$15.34$15.4102$14.61$14.8087.78K
Aug 25, 2026$15.02$15.68$14.92$15.49103K
Aug 24, 2026$15.30$15.49$14.46$14.7473.24K
Aug 21, 2026$15.54$16.1599$15.20$15.53104.91K
Aug 20, 2026$15.59$16.015$14.525$15.35207.67K
Aug 19, 2026$16.02$17.15$15.66$15.76171.05K
Aug 18, 2026$13.54$15.81$13.46$15.79311K
Aug 17, 2026$13.86$13.93$13.39$13.55132.56K
Aug 14, 2026$13.77$14.02$13.42$13.95106.07K
Aug 13, 2026$14.20$14.41$13.70$13.7489.1K
Aug 12, 2026$14.77$15.01$14.07$14.1798.15K
Aug 11, 2026$14.33$15.515$14.32$14.88134.52K
Aug 10, 2026$14.50$15.075$14.09$14.33203.11K
Aug 7, 2026$14.00$15.0869$13.945$14.71111.17K
Aug 6, 2026$14.01$15.625$13.85$14.21362.84K
Aug 5, 2026$13.50$13.975$13.20$13.45484.69K
Aug 4, 2026$12.87$13.83$12.87$13.60186.72K
Aug 3, 2026$13.05$13.15$12.71$12.8786.03K
Jul 31, 2026$13.50$13.655$12.88$12.94126.66K
Jul 30, 2026$12.98$13.74$12.82$13.72197.92K

Latest LYEL news

The latest Smart Investors Daily articles mentioning LYEL.

Stock researchCompany · Overview

LYEL research

Overview

Company profile and research snapshot.

Company profile

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$45.00
Implied upside
—
Analysts
—
LYEL recent ratings
DateFirmRatingTarget
Aug 6, 2026StifelBuy—
Jul 22, 2026B. Riley SecuritiesBuy—
Jun 15, 2026CitizensMarket Outperform—
Jun 15, 2026NeedhamBuy—
Jun 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 6, 2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the second half of 2027Presented updated ronde-cel data in more than 100 patients with relapsed/refractory LBCL at the EHA 2026 Congress, with Phase 1/2 safety data showing no Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS supporting potential outpatient administrationReported updated

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By